Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Nov 10, 2025 · Filed Nov 10, 2025
Edwards Lifesciences's CVP, JAPAC sold $84K of Edwards Lifesciences shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$84,196
Shares × reported transaction price
11 days after results of Oct 30, 2025, 92 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $84.08 on Nov 10, 2025, within 1% of its 52-week high, after a 9% rise over the previous 30 trading days
52-week range $65.81 (Nov 12, 2024) to $84.15 (Nov 4, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $77.19 on Sep 29, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.3% | -3.4% | +2.0% |
| 30 days | -1.1% | +0.9% | -2.0% |
| 90 days | -9.8% | +1.6% | -11.4% |
| 180 days | -9.4% | +8.2% | -17.6% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$951K of Edwards Lifesciences
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.